共 48 条
[1]
Friedman CF(2016)Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review JAMA Oncol 2 1346-1353
[2]
Proverbs-Singh TA(2020)Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial JAMA Oncol 6 519-527
[3]
Postow MA(2011)Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy Arthritis Rheum 63 713-721
[4]
Eggermont AMM(2016)Statin-associated autoimmune myopathy N Engl J Med 374 664-669
[5]
Kicinski M(2017)Pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies Ann Neurol 81 538-548
[6]
Blank CU(2018)Immune-mediated necrotizing myopathies working group. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016 Neuromuscul Disord 28 87-99
[7]
Mammen AL(2020)Top ten discoveries of the year: neuromuscular disease Free Neuropathology 1 4-429
[8]
Chung T(2019)Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy Neurol Neuroimmunol Neuroinflamm 6 e513-575
[9]
Christopher-Stine L(2019)Immune-mediated necrotising myopathy: a critical review of current concepts Semin Arthritis Rheum 49 420-211
[10]
Mammen AL(2019)Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy—review of the literature and future outlook J Clin Med 8 1777-82